On October 28, 2024 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present data supporting the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening adherence at the American College of Gastroenterology (ACG) 2024 Annual Meeting in Philadelphia, Oct. 25-30, 2024 (Press release, Guardant Health, OCT 28, 2024, View Source [SID1234647462]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guardant and its research partners will share real-world data demonstrating poor patient compliance with repeat stool-based screening. A study of more than 350,000 patients shows that less than half of patients who underwent stool-based CRC screening completed the retesting recommended in clinical guidelines over the following four-year period, highlighting the need for alternative options to improve overall compliance to repeat testing.

A second presentation will report on the one-year outcomes of individuals tested with Guardant’s Shield blood test for CRC screening in the ECLIPSE study to understand the implications of "false positive" results. Study results demonstrate that the rate of non-colorectal malignancies does not differ in those who tested positive with Shield compared to those who tested negative.

"Research has clearly demonstrated the value of colorectal cancer screening in detecting cancer early, when it is most treatable, but screening is only effective if an individual completes the test," said Craig Eagle, MD, chief medical officer at Guardant Health. "We look forward to sharing findings at the ACG meeting that support the potential of a blood-based screening option like the Shield test to improve overall screening rates among the millions of eligible individuals who may prefer a more pleasant screening option."

Guardant Health and collaborator presentations at ACG 2024

Presentation

Title

Time / Location

Tuesday, October 29

28

Evaluating the Risk of Non-Colorectal Cancers in Individuals With a False Positive Blood-Based Colorectal Cancer Screening Test

8:30am ET /

Terrace Ballroom 2-3

P3672

Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk – ACG Presidential Poster Award winner

10:30am-4:00pm ET / Exhibit Hall E

The full abstracts for Guardant Health and a list of all abstracts being presented at the ACG Annual Meeting can be found on the ACG meeting website.

For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook.